{"id":71737,"date":"2026-08-05T15:15:32","date_gmt":"2026-08-05T07:15:32","guid":{"rendered":"https:\/\/flcube.com\/?p=71737"},"modified":"2026-08-05T15:15:35","modified_gmt":"2026-08-05T07:15:35","slug":"allergan-aesthetics-botox-cosmetic-sbla-accepted-by-fda-for-masseter-muscle-prominence-poised-to-become-first-neurotoxin-indication","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=71737","title":{"rendered":"Allergan Aesthetics&#8217; BOTOX Cosmetic sBLA Accepted by FDA for Masseter Muscle Prominence, Poised to Become First Neurotoxin Indication"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Allergan Aesthetics<\/strong>, a subsidiary of <strong>AbbVie<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/ABBV:NYSE\">NYSE: ABBV<\/a>), announced that the <strong>U.S. Food and Drug Administration (FDA)<\/strong> has accepted its <strong>supplemental Biologics License Application (sBLA)<\/strong> for <strong>BOTOX Cosmetic<\/strong> (onabotulinumtoxinA) for the <strong>temporary improvement in the appearance of marked to very marked masseter muscle prominence (MMP)<\/strong> associated with masseter muscle activity in adults. If approved, BOTOX Cosmetic would become the <strong>first and only neurotoxin indicated for this condition in the U.S.<\/strong><\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone\" class=\"wp-block-heading\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>U.S. FDA<\/td><\/tr><tr><td><strong>Application Type<\/strong><\/td><td>Supplemental Biologics License Application (sBLA)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>BOTOX Cosmetic (onabotulinumtoxinA)<\/td><\/tr><tr><td><strong>Proposed Indication<\/strong><\/td><td>Temporary improvement of marked to very marked masseter muscle prominence (MMP)<\/td><\/tr><tr><td><strong>Target Population<\/strong><\/td><td>Adults with MMP associated with masseter muscle activity<\/td><\/tr><tr><td><strong>Market Status<\/strong><\/td><td>Potential first-in-class neurotoxin indication for MMP in U.S.<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-clinical-evidence-phase-iii-program\" class=\"wp-block-heading\">Clinical Evidence \u2013 Phase III Program<\/h2>\n\n\n\n<h3 id=\"h-study-m21-416\" class=\"wp-block-heading\">Study M21-416<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Primary Endpoint<\/strong>: Statistically significant improvement in MMP severity vs. placebo<\/li>\n\n\n\n<li><strong>Statistical Significance<\/strong>: p=0.0046<\/li>\n\n\n\n<li><strong>Study Design<\/strong>: Randomized, double-blind, placebo-controlled<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-study-m21-417\" class=\"wp-block-heading\">Study M21-417<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Primary Endpoint<\/strong>: Statistically significant improvement in MMP severity vs. placebo<\/li>\n\n\n\n<li><strong>Statistical Significance<\/strong>: p=0.0014<\/li>\n\n\n\n<li><strong>Study Design<\/strong>: Randomized, double-blind, placebo-controlled<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-safety-profile\" class=\"wp-block-heading\">Safety Profile<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Consistency<\/strong>: Safety profile consistent with established BOTOX Cosmetic uses<\/li>\n\n\n\n<li><strong>New Signals<\/strong>: No new safety signals identified<\/li>\n\n\n\n<li><strong>Tolerability<\/strong>: Well-tolerated in adult population with MMP<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-opportunity-amp-competitive-landscape\" class=\"wp-block-heading\">Market Opportunity &amp; Competitive Landscape<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Unmet Need<\/strong>: Currently no FDA-approved neurotoxin treatments specifically for masseter muscle prominence<\/li>\n\n\n\n<li><strong>Off-Label Use<\/strong>: BOTOX Cosmetic currently used off-label by aesthetic practitioners for jaw slimming<\/li>\n\n\n\n<li><strong>Market Validation<\/strong>: Formal indication would legitimize and expand clinical adoption<\/li>\n\n\n\n<li><strong>Competitive Moat<\/strong>: First-mover advantage in regulatory approval creates significant barrier to entry<\/li>\n\n\n\n<li><strong>Revenue Potential<\/strong>: Addresses growing demand for non-surgical facial contouring procedures<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-implications-for-abbvie-allergan-aesthetics\" class=\"wp-block-heading\">Strategic Implications for AbbVie\/Allergan Aesthetics<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Portfolio Expansion<\/strong>: Extends BOTOX Cosmetic&#8217;s dominance beyond existing aesthetic indications<\/li>\n\n\n\n<li><strong>Brand Reinforcement<\/strong>: Strengthens position as gold standard in neuromodulator market<\/li>\n\n\n\n<li><strong>Commercial Leverage<\/strong>: Enables targeted marketing and physician education programs<\/li>\n\n\n\n<li><strong>Pricing Power<\/strong>: Premium positioning supported by first-in-class regulatory status<\/li>\n\n\n\n<li><strong>Global Pathway<\/strong>: U.S. approval may facilitate submissions in other international markets<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-context-amp-consumer-trends\" class=\"wp-block-heading\">Market Context &amp; Consumer Trends<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Aesthetic Evolution<\/strong>: Shift toward comprehensive facial aesthetics beyond traditional forehead\/wrinkle treatments<\/li>\n\n\n\n<li><strong>Demographic Demand<\/strong>: Growing interest in jawline definition and facial contouring across diverse patient populations<\/li>\n\n\n\n<li><strong>Social Media Influence<\/strong>: Increased awareness of facial aesthetics driven by digital platforms<\/li>\n\n\n\n<li><strong>Non-Surgical Preference<\/strong>: Strong consumer preference for minimally invasive alternatives to surgical procedures<\/li>\n\n\n\n<li><strong>Treatment Frequency<\/strong>: Potential for repeat treatments aligns with BOTOX Cosmetic&#8217;s established treatment paradigm<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-forward-commercial-outlook\" class=\"wp-block-heading\">Forward Commercial Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Regulatory Timeline<\/strong>: Standard review period expected; potential approval in 2027<\/li>\n\n\n\n<li><strong>Market Access<\/strong>: Immediate commercial launch capability through existing Allergan Aesthetics infrastructure<\/li>\n\n\n\n<li><strong>Physician Education<\/strong>: Comprehensive training programs to support optimal treatment protocols<\/li>\n\n\n\n<li><strong>Consumer Marketing<\/strong>: Targeted campaigns to raise awareness of FDA-approved indication<\/li>\n\n\n\n<li><strong>Reimbursement Strategy<\/strong>: Self-pay aesthetic market with established pricing precedent<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory approvals, market opportunities, and commercial potential. Actual outcomes may differ due to risks including final FDA decisions, competitive dynamics, and market adoption.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Allergan Aesthetics, a subsidiary of AbbVie (NYSE: ABBV), announced that the U.S. Food and Drug&#8230;<\/p>\n","protected":false},"author":1,"featured_media":71738,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[234,435,38,100,853],"class_list":["post-71737","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-abbvie","tag-allergan-aesthetics","tag-market-approval-filings","tag-medical-aesthetics","tag-nyse-abbv"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Allergan Aesthetics&#039; BOTOX Cosmetic sBLA Accepted by FDA for Masseter Muscle Prominence, Poised to Become First Neurotoxin Indication - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Allergan Aesthetics, a subsidiary of AbbVie (NYSE: ABBV), announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental Biologics License Application (sBLA) for BOTOX Cosmetic (onabotulinumtoxinA) for the temporary improvement in the appearance of marked to very marked masseter muscle prominence (MMP) associated with masseter muscle activity in adults. If approved, BOTOX Cosmetic would become the first and only neurotoxin indicated for this condition in the U.S.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=71737\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Allergan Aesthetics&#039; BOTOX Cosmetic sBLA Accepted by FDA for Masseter Muscle Prominence, Poised to Become First Neurotoxin Indication\" \/>\n<meta property=\"og:description\" content=\"Allergan Aesthetics, a subsidiary of AbbVie (NYSE: ABBV), announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental Biologics License Application (sBLA) for BOTOX Cosmetic (onabotulinumtoxinA) for the temporary improvement in the appearance of marked to very marked masseter muscle prominence (MMP) associated with masseter muscle activity in adults. If approved, BOTOX Cosmetic would become the first and only neurotoxin indicated for this condition in the U.S.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=71737\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-05T07:15:32+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-05T07:15:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/0504.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71737#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71737\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Allergan Aesthetics&#8217; BOTOX Cosmetic sBLA Accepted by FDA for Masseter Muscle Prominence, Poised to Become First Neurotoxin Indication\",\"datePublished\":\"2026-08-05T07:15:32+00:00\",\"dateModified\":\"2026-08-05T07:15:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71737\"},\"wordCount\":491,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71737#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/0504.webp\",\"keywords\":[\"AbbVie\",\"Allergan Aesthetics\",\"Market approval filings\",\"Medical aesthetics\",\"NYSE: ABBV\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=71737#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71737\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=71737\",\"name\":\"Allergan Aesthetics' BOTOX Cosmetic sBLA Accepted by FDA for Masseter Muscle Prominence, Poised to Become First Neurotoxin Indication - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71737#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71737#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/0504.webp\",\"datePublished\":\"2026-08-05T07:15:32+00:00\",\"dateModified\":\"2026-08-05T07:15:35+00:00\",\"description\":\"Allergan Aesthetics, a subsidiary of AbbVie (NYSE: ABBV), announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental Biologics License Application (sBLA) for BOTOX Cosmetic (onabotulinumtoxinA) for the temporary improvement in the appearance of marked to very marked masseter muscle prominence (MMP) associated with masseter muscle activity in adults. If approved, BOTOX Cosmetic would become the first and only neurotoxin indicated for this condition in the U.S.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71737#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=71737\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71737#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/0504.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/0504.webp\",\"width\":1080,\"height\":608,\"caption\":\"Allergan Aesthetics' BOTOX Cosmetic sBLA Accepted by FDA for Masseter Muscle Prominence, Poised to Become First Neurotoxin Indication\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71737#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Allergan Aesthetics&#8217; BOTOX Cosmetic sBLA Accepted by FDA for Masseter Muscle Prominence, Poised to Become First Neurotoxin Indication\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Allergan Aesthetics' BOTOX Cosmetic sBLA Accepted by FDA for Masseter Muscle Prominence, Poised to Become First Neurotoxin Indication - Insight, China&#039;s Pharmaceutical Industry","description":"Allergan Aesthetics, a subsidiary of AbbVie (NYSE: ABBV), announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental Biologics License Application (sBLA) for BOTOX Cosmetic (onabotulinumtoxinA) for the temporary improvement in the appearance of marked to very marked masseter muscle prominence (MMP) associated with masseter muscle activity in adults. If approved, BOTOX Cosmetic would become the first and only neurotoxin indicated for this condition in the U.S.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=71737","og_locale":"en_US","og_type":"article","og_title":"Allergan Aesthetics' BOTOX Cosmetic sBLA Accepted by FDA for Masseter Muscle Prominence, Poised to Become First Neurotoxin Indication","og_description":"Allergan Aesthetics, a subsidiary of AbbVie (NYSE: ABBV), announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental Biologics License Application (sBLA) for BOTOX Cosmetic (onabotulinumtoxinA) for the temporary improvement in the appearance of marked to very marked masseter muscle prominence (MMP) associated with masseter muscle activity in adults. If approved, BOTOX Cosmetic would become the first and only neurotoxin indicated for this condition in the U.S.","og_url":"https:\/\/flcube.com\/?p=71737","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-08-05T07:15:32+00:00","article_modified_time":"2026-08-05T07:15:35+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/0504.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=71737#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=71737"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Allergan Aesthetics&#8217; BOTOX Cosmetic sBLA Accepted by FDA for Masseter Muscle Prominence, Poised to Become First Neurotoxin Indication","datePublished":"2026-08-05T07:15:32+00:00","dateModified":"2026-08-05T07:15:35+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=71737"},"wordCount":491,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=71737#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/0504.webp","keywords":["AbbVie","Allergan Aesthetics","Market approval filings","Medical aesthetics","NYSE: ABBV"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=71737#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=71737","url":"https:\/\/flcube.com\/?p=71737","name":"Allergan Aesthetics' BOTOX Cosmetic sBLA Accepted by FDA for Masseter Muscle Prominence, Poised to Become First Neurotoxin Indication - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=71737#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=71737#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/0504.webp","datePublished":"2026-08-05T07:15:32+00:00","dateModified":"2026-08-05T07:15:35+00:00","description":"Allergan Aesthetics, a subsidiary of AbbVie (NYSE: ABBV), announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental Biologics License Application (sBLA) for BOTOX Cosmetic (onabotulinumtoxinA) for the temporary improvement in the appearance of marked to very marked masseter muscle prominence (MMP) associated with masseter muscle activity in adults. If approved, BOTOX Cosmetic would become the first and only neurotoxin indicated for this condition in the U.S.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=71737#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=71737"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=71737#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/0504.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/0504.webp","width":1080,"height":608,"caption":"Allergan Aesthetics' BOTOX Cosmetic sBLA Accepted by FDA for Masseter Muscle Prominence, Poised to Become First Neurotoxin Indication"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=71737#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Allergan Aesthetics&#8217; BOTOX Cosmetic sBLA Accepted by FDA for Masseter Muscle Prominence, Poised to Become First Neurotoxin Indication"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/0504.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/71737","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=71737"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/71737\/revisions"}],"predecessor-version":[{"id":71739,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/71737\/revisions\/71739"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/71738"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=71737"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=71737"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=71737"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}